Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease
复制标题
DOI：
10.1586/eci.10.40
复制
发表时间：
2010-07-01
影响因子：
4.4
通讯作者：
Danese, Silvio
中科院分区：
文献类型：
--
作者：
Fiorino, Gionata;Correale, Carmen;Danese, Silvio
炎症性肠病具有共同的发病机制，但尚未完全了解。然而，很明显，响应于炎症的细胞因子的表达和产生在介导活化的白细胞的迁移中起关键作用。血管生成过程和粘附分子在肠微血管系统上的表达充当网关，促进白细胞募集到肠粘膜中。已经开发了特异性阻断粘附分子（特别是整联蛋白）的新试剂，以限制活化的白细胞进入粘膜。非肠道特异性抗整合蛋白药物，如那他珠单抗，已被证明在治疗IBD中有效，但严重不良事件的风险限制了其进一步发展。目前正在一项大型临床试验中研究一种新的特异性分子Vedolizumab的开发。这种新型的特异性抗整合素药物似乎有望治疗肠道炎症。
Inflammatory bowel bowel diseases share common pathogenetic mechanisms that are not yet completely understood. It is clear, however, that the expression and production of cytokines in response to inflammation plays a key role in mediating the migration of activated leukocytes. The process of angiogenesis and the expression of adhesion molecules on the intestinal microvasculature act as gateways, facilitating the recruitment of leukocytes into the gut mucosa. New agents specifically blocking adhesion molecules, in particular integrins, have been developed in order to limit the passage of activated leukocytes into the mucosa. Non-gut-specific anti-ntegrin agents, such as natalizumab, have been shown to be effective in the treatment of IBD, but the risk of serious adverse events has limited their further development. The development of a new specific molecule, vedolizumab, is currently under investigation in a large clinical trial. This novel specific anti-integrin drug seems to hold promise in the treatment of gut inflammation.